Unprecedented Cat Outbreak Unleashes Chaos in Cyprus
Cyprus, a haven for over a million free-roaming cats, is currently grappling with a deadly outbreak that has left both stray and pet cats dead. The disease responsible, feline infectious peritonitis (FIP), has seen a staggering 20-fold increase in lab-confirmed cases on the Mediterranean island. The outbreak has left veterinarians mystified, sparking speculations about the potential impact of COVID-19, another coronavirus known to infect cats.
FIP is an almost 100 percent fatal disease in cats, characterized by swollen bellies resembling bowling balls, and has never before spread across an entire island with such devastating consequences. However, amidst the chaos, a silver lining emerged — the discovery that COVID antivirals can effectively treat FIP. The similarities between the two coronaviruses have paved the way for miracle cures, breathing new hope into the fight against FIP.
The emergence of effective antiviral drugs against FIP was greatly accelerated by the global research surge prompted by COVID-19. Previously, cat owners could only obtain black-market versions of these drugs. However, the surplus stockpiles of the COVID antiviral, molnupiravir, has allowed Cyprus to combat the outbreak by making the treatment available to affected cats. This fortunate turn of events has spared countless feline lives, much to the relief of the country’s residents.
The first signs of the outbreak were noticed in early 2023, with the capital city of Nicosia being the initial epicenter. However, the cases soon spread to the most remote regions of the island, suggesting a novel pathogen was responsible for the outbreak. FIP is a virus that affects cats in varied and unpredictable ways. While most cats experience mild or no symptoms, a small minority, usually those under stress or with a genetic predisposition, suffer severe disease. Scientists are currently focusing on the possibility of a unique and highly virulent strain of FIP that may be responsible for the epidemic.
Experts are also considering the potential link between the FIP outbreak and the global COVID-19 pandemic. The feline coronavirus and SARS-CoV-2 are genetically distinct, making direct recombination unlikely. However, researchers are exploring the theory that previous exposure to COVID-19 may exacerbate FIP symptoms, echoing the unpredictable consequences of the pandemic.
Treatment for FIP was once non-existent, but a breakthrough in 2018 offered hope. A drug similar to the antiviral remdesivir was successfully tested in cats, leading to a remarkable 100 percent cure rate. Since then, the availability of effective antiviral drugs has significantly increased, with molnupiravir and remdesivir being utilized for FIP treatment. The recent introduction of molnupiravir in curing FIP has been met with great success worldwide.
However, the availability of these drugs remains a challenge, particularly due to counterfeit products circulating on the black market. The exorbitant cost of the medication, reaching thousands of U.S. dollars per cat, combined with concerns about the purity and dosage of these unlicensed drugs, highlights the need for accessible and reliable treatment options. With the Cypriot government’s decision to release stockpiles of molnupiravir, the situation in Cyprus has taken a positive turn, providing veterinarians with a valuable tool in the battle against FIP.
While molnupiravir may not be the optimal drug for FIP due to toxicity concerns and the potential for viral mutations, its affordability and availability make it the most viable option in many regions. Furthermore, the drug’s potential approval for COVID treatment could pave the way for its official use in cats, ultimately offering a legal solution for FIP treatment worldwide.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
